Ignite Creation Date:
2025-12-24 @ 9:24 PM
Ignite Modification Date:
2026-02-22 @ 9:39 AM
Study NCT ID:
NCT02957032
Status:
TERMINATED
Last Update Posted:
2023-10-10
First Post:
2016-10-17
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Sponsor:
Philogen S.p.A.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
PH-F16IL2CYT-03/14
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None